CVS HEALTH Corp CVS
NYSE · XNYS · stock · Retail-Drug Stores and Proprietary Stores
Chart by TradingView
5/9
Piotroski F — financial health
0.99
Altman Z″ — distress risk · distress
192.1%
Dividend payout · at-risk
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $402.1B | $1.8B | — | $7.8B | $75.2B |
| 2024 | $372.8B | $4.6B | — | $6.3B | $75.7B |
| 2023 | $357.8B | $8.3B | — | $10.4B | $76.6B |
| 2022 | $322.5B | $4.3B | — | $13.4B | $71.8B |
| 2021 | $292.1B | $8.0B | — | $15.7B | $74.8B |
| 2020 | $268.7B | $7.2B | — | $13.4B | $69.7B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.99 (distress)
- Working capital / assets -0.055
- Retained earnings / assets 0.241
- EBIT / assets 0.018
- Equity / liabilities 0.422
Source: SEC EDGAR filings · CIK 0000064803 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.